Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of switching tenofovir disoproxil fumarate to tenofovir alafenamide in HIV and chronic hepatitis B co-infection
2017-002385-49Phase 4Unknown
- Sponsor
- King's College Hospital
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) and Chronic Hepatitis B (CHB), sponsored by King's College Hospital. Primary endpoints: Feasibility and tolerability of switching TDF to TAF and Effect on glomerular function. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2017-002385-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002385-49.